There is evidence showing that central appetite regulation is sexually dimorphic [273,274], and therefore targeted investigations of oxytocin effects in females would be critical to pursue in order to allow the development of this drug as an effective anti-obesity pharmacotherapy. The gene discussed is OXT; the disease is obesity due to melanocortin 4 receptor deficiency.